
Claims

1. Use of a compound of formula I:



Formula I

or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the compound of formula I or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein:


R^1 is halo;

R^2 is halo; and

Q is CH or N;

in combination with atezolizumab, in the manufacture of a medicament for treating locally advanced or metastatic solid tumors, wherein the locally advanced or metastatic solid tumors is castration-recurrent prostate cancer (CRPC).

2. The use of claim 1, wherein the compound of formula I is compound 1, or a pharmaceutically acceptable salt thereof.



Compound 1

3. The use of claim 2, wherein compound 1 is to be administered as the L-malate salt (or S-malate salt).

4. The use of claim 2, wherein compound 1 is to be administered as the D-malate salt (or R-malate salt).

5. The use of any one of claims 2-4 wherein atezolizumab is to be administered intravenously (IV).

6. The use of any one of claims 2-5, wherein Compound 1 or a pharmaceutically acceptable salt thereof and atezolizumab are to be administered concurrently or sequentially.

7. The use of claim 6, wherein up to and including 1,200 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

8. The use of claim 7, wherein up to and including 1,200 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 60 mg, 40 mg, or 20 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

9. The use of claim 6, wherein up to and including 1,100 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

10. The use of claim 9, wherein up to and including 1,100 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 60 mg, 40 mg, or 20 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

11. The use of claim 6, wherein up to and including 1,000 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

12. The use of claim 11, wherein up to and including 1,000 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 60 mg, 40 mg, or 20 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

13. The use of claim 6, wherein up to and including 900 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 100 mg, 95 mg, 90 mg, 85 mg, 80 mg, 75 mg, 70 mg, 65 mg, 60 mg, 55 mg, 50 mg, 45 mg, 40 mg, 35 mg, 30 mg, 25 mg, 20 mg, 15 mg, 10 mg, or 5 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

14. The use of claim 13, wherein up to and including 900 mg of atezolizumab is to be administered to the patient once every three weeks in combination with 60 mg, 40 mg, or 20 mg of compound 1, or a pharmaceutically acceptable salt thereof, once daily with fasting.

15. The use of any one of claims 6-14, wherein the atezolizumab is to be administered intravenously via infusion over 60 minutes or 30 minutes.

16. The use of any one of claims 1-15, wherein a complete serological response is observed in patients being treated with the combination.

17. The use of any one of claims 1-15, wherein a serological partial response is observed in patients being treated with the combination.

18. The use of any one of claims 1-15, wherein stable disease is observed in patients being treated with the combination.